<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168073">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01783899</url>
  </required_header>
  <id_info>
    <org_study_id>Hemospray Varices</org_study_id>
    <nct_id>NCT01783899</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Hemospray in Hemostasis of Active Variceal Bleeding</brief_title>
  <official_title>Clinical Evaluation of Hemospray in Hemostasis of Active Variceal Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theodor Bilharz Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Université Libre de Bruxelles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Theodor Bilharz Research Institute</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the effectiveness of Hemospray in achieving initial
      hemostasis and decreased rate of re-bleeding in patients of acute variceal bleeding.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">April 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety will be characterized by the incidence of all Adverse Device Effects (ADEs), non-serious and serious, possibly related to or related to the procedure and/or device that are experienced by study participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Information on efficacy will be obtained by measurements the proportion of patients with acute (procedural) hemostasis, and the rate of recurrent bleeding within 72 hours of treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Variceal Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Hemospray Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemospray device consists of a syringe containing the Hemospray powder (21 g per syringe), a delivery catheter that will be inserted into the working channel of the endoscope, and an introducer handle with a built-in carbon dioxide canister to propel the Hemospray powder out of the catheter.
In addition to Hemospray device any other required endoscopic accessories can be used during the procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hemospray</intervention_name>
    <description>Patients will be resuscitated as needed to achieve hemodynamic stability in preparation for endoscopy within 24 hours of hospital admission.
once the bleeding point will be identified at endoscopy, the delivery catheter will be inserted through the endoscope and positioned toward the lesion, leaving 1-2 cm between the bleeding site and the catheter tip.
Hemospray will be then delivered in short spray bursts (for 1-2 seconds) until hemostasis was confirmed.
Once bleeding was controlled , the bleeding site will be observed for 5 minutes under endoscopy.
Oral food and fluid will be with held from the patient for 24 hours. Intravenous octreotide and esomeprazole will given for up to 24 hours. Patients will be closely monitored for signs of recurrent bleeding for 24 hours post procedure.
Recurrent bleeding will be diagnosed any patient experiencing recurrent bleeding will treated according to the institutional standard of care</description>
    <arm_group_label>Hemospray Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  18 Years and older

          -  Bleeding Esophageal and / or Gastric varices

        Exclusion Criteria:

          -  Patient is: &lt; 18 years of age

          -  Unable to consent

          -  Contraindicated to undergo endoscopy,

          -  Already hospitalized for another illness

          -  Pregnant or lactating

          -  Patients with altered post-surgical anatomy of the stomach

          -  Previously placed intrahepatic portosystemic shunt

          -  Patient treated by other endoscopic or surgical modalities within 7 days prior to the
             intended application of Hemospray
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mostafa Ibrahim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université Libre de Bruxelles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mostafa Ibrahim, MD</last_name>
    <phone>00201006107100</phone>
    <email>mostafa.ibrahim@me.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Erasme Hospital , ULB</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques , Deviere</last_name>
      <phone>003225553712</phone>
      <email>jacques.deviere@erasme.ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Jacques Deviere, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mostafa Ibrahim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Theodor Bilharz Research Institute</name>
      <address>
        <city>Giza</city>
        <zip>12311</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ibrahim Mostafa, PhD</last_name>
      <phone>00201222113466</phone>
      <email>ibrahimmostafa@egyptgastrohep.com</email>
    </contact>
    <investigator>
      <last_name>Ibrahim Mostafa, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed El Mikkawy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mostafa Ibrahim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 4, 2013</lastchanged_date>
  <firstreceived_date>February 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Theodor Bilharz Research Institute</investigator_affiliation>
    <investigator_full_name>Mostafa Ibrahim</investigator_full_name>
    <investigator_title>Gastroenterologist</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
